RNASE1

Across TCGA pan-cancer cohorts, RNASE1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RNASE1 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher RNASE1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RNASE1 expression acts as an unfavorable survival marker.

STAD, COAD, and LIHC are the cancer types where RNASE1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	II,III,IV	0.184	0.710	.001	21	view →
COAD	OS	Median	All	0.113	0.806	<.001	12	view →
LIHC	OS	Median	III,IV	0.270	0.732	.021	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RNASE1–STAD (OS)

Open the STAD breakdown →